From the Experimental and Clinical Research Center (T.-Y.L., V.V., S.A., I.M.S., S.M., C.C., A.P., J.B.-S., F.P., A.U.B., H.G.Z.), Max-Delbrück Center for Molecular Medicine and Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; NeuroCure Clinical Research Center (T.-Y.L., V.V., S.A., I.M.S., S.M., C.C., A.P., J.B.-S., F.P., A.U.B., H.G.Z.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Department of Psychiatry and Psychotherapy (C.C.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health; Department of Statistics (M.D.), TU Dortmund University, Germany; Neurology Clinic and Policlinic (A.P., J.K.), MS Center and Research Center for Clinical Neuroimmunology and Neuroscience Basel (RC2NB), University Hospital Basel; Clinical Trial Unit (P.B.), Department of Clinical Research, University Hospital Basel, University of Basel, Switzerland; Department of Neurology (K.R., F.P.), Charité-Universitätsmedizin Berlin, corporate member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Germany; and Department of Neurology (A.U.B.), University of California, Irvine.
Neurol Neuroimmunol Neuroinflamm. 2021 Aug 4;8(5). doi: 10.1212/NXI.0000000000001051. Print 2021 Sep.
To investigate the association of combined serum neurofilament light chain (sNfL) and retinal optical coherence tomography (OCT) measurements with future disease activity in patients with early multiple sclerosis (MS).
We analyzed sNfL by single molecule array technology and performed OCT measurements in a prospective cohort of 78 patients with clinically isolated syndrome and early relapsing-remitting MS with a median (interquartile range) follow-up of 23.9 (23.3-24.7) months. Patients were grouped into those with abnormal or normal sNfL levels, defined as sNfL ≥/<80th percentile of age-corrected reference values. Likewise, patients were grouped by a median split into those with thin or thick ganglion cell and inner plexiform layer (GCIP), peripapillary retinal nerve fiber layer, and inner nuclear layer in nonoptic neuritis eyes. Outcome parameters were violation of no evidence of disease activity (NEDA-3) criteria or its components.
Patients with abnormal baseline sNfL had a higher risk of violating NEDA-3 (hazard ratio [HR] 2.28, 95% CI 1.27-4.09, = 0.006) and developing a new brain lesion (HR 2.47, 95% CI 1.30-4.69, = 0.006), but not for a new relapse (HR 2.21, 95% CI 0.97-5.03, p = 0.058). Patients with both abnormal sNfL and thin GCIP had an even higher risk for NEDA-3 violation (HR 3.61, 95% CI 1.77-7.36, = 4.2e), new brain lesion (HR 3.19, 95% CI 1.51-6.76, = 0.002), and new relapse (HR 5.38, 95% CI 1.61-17.98, = 0.006) than patients with abnormal sNfL alone.
In patients with early MS, the presence of both abnormal sNfL and thin GCIP is a stronger risk factor for future disease activity than the presence of each parameter alone.
探讨联合血清神经丝轻链(sNfL)和视网膜光相干断层扫描(OCT)测量值与早期多发性硬化症(MS)患者未来疾病活动的相关性。
我们通过单分子阵列技术分析 sNfL,并对 78 例临床孤立综合征和早期复发缓解型 MS 患者进行前瞻性队列研究,中位(四分位间距)随访时间为 23.9(23.3-24.7)个月。患者根据 sNfL 水平分为异常或正常组,定义为 sNfL≥/<80 百分位数的年龄校正参考值。同样,根据中位数将患者分为非视神经炎眼的神经节细胞和内丛状层(GCIP)、神经纤维层和内核层薄或厚的组。结局参数为违反无疾病活动证据(NEDA-3)标准或其成分。
基线 sNfL 异常的患者违反 NEDA-3 的风险更高(风险比[HR]2.28,95%CI1.27-4.09, =0.006),新发脑病变(HR2.47,95%CI1.30-4.69, =0.006)的风险也更高,但新发复发(HR2.21,95%CI0.97-5.03,p=0.058)的风险没有更高。sNfL 异常和 GCIP 变薄的患者同时违反 NEDA-3 的风险更高(HR3.61,95%CI1.77-7.36, =4.2e),新发脑病变(HR3.19,95%CI1.51-6.76, =0.002)和新发复发(HR5.38,95%CI1.61-17.98, =0.006)的风险也更高,而单独 sNfL 异常的患者则没有。
在早期 MS 患者中,sNfL 异常和 GCIP 变薄同时存在是未来疾病活动的一个更强的危险因素,比单独存在每个参数的风险更大。